Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Neurologic Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Neurologic Other
    MRI Can Predict Outcome of Infants Deficient of Oxygen at Birth - (DGNews)
    Brain Tumours In Childhood Leave a Lasting Mark On Cognition, Life Status - (DGNews)
    Rifaximin Protects Patients With Cirrhosis From Breakthrough Hepatic Encephalopathy Over Long Term: Presented at AASLD - (DGDispatch)
    Neurocognitive Issues Plague HIV-Infected Patients Taking Antiretroviral Therapy: Presented at IDSA - (DGDispatch)
    Vaccine Inoculations Show No Link to Autism, Other Health Problems: Presented at IDSA - (DGDispatch)

    News archive

     Recent webcasts/CME - Neurologic Other
      Therapeutic Hypothermia
      Arteriovenous Malformations Dural Arteriovenous Shunts
      PreAnesthetic Assessment of the Patient with Neurotrauma
      Generalized Convulsive Status Epilepticus Guillain Barre Syndrome
      High-Risk Transient Ischemic Attacks Clinical Uses of Transcranial Doppler

      Webcasts/CME archive

       Recent cases - Neurologic Other
        Giant Thoracic Schwannoma Presenting with Abrupt Onset of Abdominal Pain: A Case Report
        Atypical Imaging Findings in a Renal Transplant Patient with Reversible Posterior Leukoencephalopathy Syndrome: A Case Report
        Reversible Cerebellar Syndrome Caused by Metronidazole
        A Patient with Typical Clinical Features of Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS) but Without an Obvious Genetic Cause: A Case Report
        Spinal Subdural Haematoma in Association With Anticoagulant Therapy, an Unusual Presentation. A Case Report and Review of Literature

        Cases archive
          




        my personal edition > neurologic other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Bupropion May Aid Patients With Inflammatory Bowel Disease: Presented at SFN

        By Roberta Friedman, PhD

        NEW ORLEANS, LA -- November 10, 2003 -- A drug for psychiatric conditions may have a new use in treating inflammatory bowel disease if pilot data presented here November 8th at Neuroscience 2003, the Society for Neuroscience 33rd Annual Meeting, bear out in larger trials.

        Bupropion lowered levels of tumor necrosis factor (TNF) in 8 patients who were taking bupropion for depression, with 7 entering the normal range for the inflammatory agent. Levels of TNF ranged from 20 to 1250 pg/mL before bupropion, and dropped to 14 to 2 pg/ml afterwards. One patient's levels remained elevated, at 94 pg/mL.

        Larger studies are underway, in Crohn's disease, and in other diseases linked with TNF.

        Prior publication by the investigators indicated that some patients taking the agent have remission of Crohn's symptoms. Another short paper in press duplicates the finding. Psoriasis apparently also improves with the drug treatment, according to another, recent paper.

        "There are a lot of TNF-[related] diseases," said investigator Dr. Eric Altschuler, resident, rehabilitation medicine, Mt. Sinai Medical Center, New York, New York. "Obviously large, randomized trials are needed [to show the effect of bupropion on TNF is real]," said Dr. Altschuler, but, he added, "if this is true, [bupropion] is cheap, safe, and it's easy [to give]. Doctors have a good comfort level [with the drug]."

        The investigators speculate that the result with TNF comes about through activation of dopamine, which increases cyclic adenosine monophosphate inside cells, thereby decreasing the manufacture of TNF by macrophages.

        Dr. Altschuler is an inventor listed on a patent application for use of bupropion as a TNF-lowering agent, filed by the University of California. He is also an advisor to GlaxoSmithKline.


        [Study title: Bupropion (Wellbutrin) Lowers Tumor Necrosis Factor-Alpha (TNF) Levels: Implications for Disease Treatment. Abstract 105.8]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send